4.7 Article

Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

期刊

PHARMACEUTICS
卷 15, 期 3, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics15030885

关键词

technetium-99m; somatostatin receptor antagonists; kit formulation; single dose toxicity; SPECT; radiopharmaceuticals; neuroendocrine neoplasms

向作者/读者索取更多资源

The broad availability and cost-effectiveness of Mo-99/Tc-99m generators worldwide have supported the use and development of novel Tc-99m-labelled radiopharmaceuticals. This study aimed to provide a reliable method for the facile preparation of a Tc-99m-labelled SST2 antagonist, [Tc-99m]Tc-TECANT-1, in a hospital radiopharmacy setting for a multi-centre clinical trial. A freeze-dried three-vial kit was successfully developed to ensure successful and reproducible on-site preparation of the radiopharmaceutical for human use shortly before administration.
Broad availability and cost-effectiveness of Mo-99/Tc-99m generators worldwide support the use, and thus the development, of novel Tc-99m-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms patient management focused on somatostatin receptor subtype 2 (SST2) antagonists, mainly due to their superiority in SST2-tumour targeting and improved diagnostic sensitivity over agonists. The goal of this work was to provide a reliable method for facile preparation of a Tc-99m-labelled SST2 antagonist, [Tc-99m]Tc-TECANT-1, in a hospital radiopharmacy setting, suitable for a multi-centre clinical trial. To ensure successful and reproducible on-site preparation of the radiopharmaceutical for human use shortly before administration, a freeze-dried three-vial kit was developed. The final composition of the kit was established based on the radiolabelling results obtained during the optimisation process, in which variables such as precursor content, pH and buffer, as well as kit formulations, were tested. Finally, the prepared GMP-grade batches met all predefined specification parameters together with long-term kit stability and stability of the product [Tc-99m]Tc-TECANT-1. Furthermore, the selected precursor content complies with micro-dosing, based on an extended single-dose toxicity study, where histopathology NOEL was established at 0.5 mg/kg BW, being more than 1000 times higher than the planned human dose of 20 mu g. In conclusion, [Tc-99m]Tc-TECANT-1 is suitable to be advanced into a first-in-human clinical trial.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据